Exenatide treatment alleviated symptoms of depression in patients
(IOS Press) Non-motor symptoms of Parkinson's disease (PD), such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits. In a post hoc analysis of the exenatide-PD trial results, investigators found that patients on exenatide treatment experienced improvements in severity of depression, independent of whether their motor function improved. They report their findings in the Journal of Parkinson's Disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2018 Category: International Medicine & Public Health Source Type: news

Incretin/SGLT-2 Combo Efficacy Persists 2 Years
(MedPage Today) -- Exenatide plus dapagliflozin maintained biomarker benefits in long-term study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2018 Category: Cardiology Source Type: news

AstraZeneca ’ s once-weekly diabetes drug wins expanded FDA approval
AstraZeneca (NYSE:AZN) said today that the FDA approved its extended-release formulation of exenatide, Bydureon, for use as an add-on therapy to basal insulin in adults with Type II diabetes. The company’s once-weekly GLP-1 injectable was first approved in the U.S. in 2012. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Source Type: news

FDA Approves Bydureon (exenatide extended-release) for Use with Basal Insulin in Patients with Type 2 Diabetes with Inadequate Glycemic Control
April 3, 2018 AstraZeneca today announced the US Food and Drug Administration (FDA) has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 3, 2018 Category: Drugs & Pharmacology Source Type: news

Exenatide (BYDUREON) Extended Release for Injectable Suspension (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - March 28, 2018 Category: Drugs & Pharmacology Source Type: news

Exenatide Influence on the Cardiac Sympatho-Vagal Balance Exenatide Influence on the Cardiac Sympatho-Vagal Balance
A new study examines the sympatho-vagal balance variations among patients with type 2 diabetes during treatment with the GLP-1 agonist exenatide.Journal of the Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 5, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Intarcia slashes headcount after FDA rejects diabetes drug-device combo
Four months after the FDA rejected its diabetes drug-eluting implant, privately-held Intarcia Therapeutics has cut 60 employees and received a clinical hold for two of its ongoing marketing studies, according to reports. The company’s device is designed for the continuous, subcutaneous delivery of exenatide in people with Type II diabetes. It was rejected by the U.S. regulatory agency in September, after the FDA found problems with the manufacturing process used to make ITCA 650. Get the full story at our sister site, Drug Delivery Business News. The post Intarcia slashes headcount after FDA rejec...
Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Implants Pharmaceuticals Intarcia Therapeutics Source Type: news

Semaglutide Bests Exenatide in Type 2 Diabetes Semaglutide Bests Exenatide in Type 2 Diabetes
Subcutaneous injection of semaglutide provides superior results to exenatide extended release (ER), also administered subcutaneously, in patients who have diabetes inadequately controlled by oral agents, according to findings from an open-label trial.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 12, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
WILMINGTON, Del., Jan. 10, 2018 -- (Healthcare Sales & Marketing Network) -- AstraZeneca today announced that BYDUREON® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the United States. BYDUREON BCi... Biopharmaceuticals, Endocrinology, Product Launch AstraZeneca, BYDUREON BCise, exenatide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 10, 2018 Category: Pharmaceuticals Source Type: news

Bydureon Bcise (Exenatide Extended-Release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 18, 2017 Category: Drugs & Pharmacology Source Type: news

Bydureon Bcise (Exenatide Extended-Release Injectable Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 14, 2017 Category: Drugs & Pharmacology Source Type: news

Targeting a microRNA shows potential to enhance effectiveness of diabetes drugs
(University of Alabama at Birmingham) Researchers have found a vital role for miR-204 in beta cells -- regulating the cell surface receptor that is the target of many of the newer type 2 diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta. This drug target is the glucagon-like peptide 1 receptor, or GLP1R. Activation of GLP1R with these drugs helps the beta cell produce and secrete more insulin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news

FDA clears AstraZeneca ’s once-weekly Type II diabetes drug-device combo
AstraZeneca (NYSE:AZN) said today that the FDA approved its once-weekly exenatide drug in a single-dose auto-injector for adults with Type II diabetes whose blood sugar is uncontrolled on one or more oral drugs. The company’s drug, Bydureon, is formulated with a continuous-release microsphere delivery system designed to provide consistent levels of exenatide, according to AstraZeneca, to reduce blood sugar levels in people with diabetes. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears AstraZeneca’s once-weekly Type II diabetes drug-device combo appeared first on Mass...
Source: Mass Device - October 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Source Type: news

FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes
23 October 2017 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon ® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 23, 2017 Category: Drugs & Pharmacology Source Type: news

FDA deals setback to Intarcia for diabetes implant
Privately-held biopharma Intarcia Therapeutics revealed today that the FDA rejected its exenatide implant, ITCA 650, designed to treat Type II diabetes. The company said that it doesn’t think it will need to conduct new pivotal trials in order to address the concerns brought about by the FDA’s complete response letter. Get the full story at our sister site, Drug Delivery Business News. The post FDA deals setback to Intarcia for diabetes implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - September 28, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Implants Pharmaceuticals Regulatory/Compliance Intarcia Therapeutics Source Type: news

GLP-1 diabetes drug neutral for the heart
Extended-release exenatide (Bydureon) is safe for the heart but does not help prevent cardiovascular events in type 2 diabetes, a study published in theNew England Journal of Medicinereports.MedPage Today (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 15, 2017 Category: Endocrinology Source Type: news

In Type 2 Diabetes, Adding Once-Weekly Exenatide Doesn't Improve CV Outcomes (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Adding the injectable type 2 diabetes drug exenatide (Byetta) to usual care does not improve cardiovascular outcomes, according to an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 14, 2017 Category: Primary Care Source Type: news

GLP-1 Diabetes Drug Neutral for the Heart (CME/CE)
(MedPage Today) -- Once-weekly exenatide safe for CV outcomes but falls short of showing benefit (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - September 14, 2017 Category: Endocrinology Source Type: news

EXSCEL:'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes EXSCEL:'Disappointment' Spurs Discussion on GLP-1 Agonists in Diabetes
Full details of EXSCEL with the GLP-1 agonist exenatide, in which the agent didn't show any cardiovascular benefit over placebo in type 2 diabetes, provide"some good news" but also"some disappointment."Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 14, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

A1c, Weight Loss Benefit Seen With Exenatide-Glargine Combo
(MedPage Today) -- No increased risk for hypoglycemia reported (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 12, 2017 Category: Cardiology Source Type: news

More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). (Source: World Pharma News)
Source: World Pharma News - September 12, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Scientists Discover Existing Diabetes Drug Reduces Sight-threatening...
Research led by the University of Birmingham, UK, published in Science Translational Medicine, shows that a GLP-1 receptor agonist drug, Exenatide, treats raised brain pressure in animal models.(PRWeb September 07, 2017)Read the full story at http://www.prweb.com/releases/2017/09/prweb14659458.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 7, 2017 Category: Pharmaceuticals Source Type: news

Diabetes Drug May Slow Parkinson's Disease Diabetes Drug May Slow Parkinson's Disease
Exenatide improved off-medication motor scores in patients with Parkinson's disease in a placebo-controlled trial, and the benefits persisted for several weeks after the drug was discontinued.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

UCL research indicates use of diabetes drug in Parkinson ’s disease
University College London (UCL) has carried out a study that indicated the potential of a common diabetes drug called exenatide as a disease-modifying therapy for treating Parkinson ’s disease. (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Diabetes Drug Shows Promise Against Parkinson's
Byetta improved symptoms of motor disease in small, short trial, but more research needed (Source: WebMD Health)
Source: WebMD Health - August 4, 2017 Category: Consumer Health News Source Type: news

Diabetes drug may be helpful for Parkinson's disease
Conclusion This research shows some interesting early findings, though the magnitude of effect was very small compared to the improvements in symptoms with current dopaminergic drugs. The study was well conducted but did have some limitations: The number of people taking part was quite small. This may have meant it was hard to detect any other benefits or harms of taking the drug other than the effects on motor scores. The period of time people were given the drug and followed up meant that longer-term effects could not be measured. The benefit of the drug observed so far might not be big enough to make a difference ...
Source: NHS News Feed - August 4, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

Diabetes Drug Shows Promise Against Parkinson's
Byetta improved symptoms of motor disease in small, short trial, but more research needed Source: HealthDay Related MedlinePlus Pages: Diabetes Medicines, Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 4, 2017 Category: Consumer Health News Source Type: news

Medical News Today: Diabetes shot boosts motor function for patients with Parkinson's
A placebo trial shows that the diabetes drug exenatide improved motor symptoms of Parkinson's disease and may have disease-altering potential. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 4, 2017 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news

Diabetes shot boosts motor function for patients with Parkinson's
A placebo trial shows that the diabetes drug exenatide improved motor symptoms of Parkinson's disease and may have disease-altering potential. (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - August 4, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news

Diabetes Drug, Exenatide, Shows Promise Against Parkinson's
FRIDAY, Aug. 4, 2017 -- The diabetes drug exenatide (Byetta) may do double duty as a treatment for Parkinson's disease, a new study suggests. " This is a very promising finding, as the drug holds potential to affect the course of the disease itself,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 4, 2017 Category: General Medicine Source Type: news

Diabetes Drug Shows Promise Against Parkinson's
FRIDAY, Aug. 4, 2017 -- The diabetes drug exenatide (Byetta) may do double duty as a treatment for Parkinson's disease, a new study suggests. " This is a very promising finding, as the drug holds potential to affect the course of the disease itself,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 4, 2017 Category: General Medicine Source Type: news

Diabetes drug could help those living with Parkinson's disease
A study published inThe Lancet suggests that exenatide improves movement-related issues and might also slow the progression of the disease.The Guardian (Source: Society for Endocrinology)
Source: Society for Endocrinology - August 4, 2017 Category: Endocrinology Source Type: news

Diabetes drug could help those living with Parkinson's disease, research reveals
Study suggests that exenatide, currently used to treat type 2 diabetes, improves movement-related issues and might also slow the progression of the diseaseA drug commonly used to treat diabetes could help those living with Parkinson ’s disease, research has revealed.By 2020 it is predicted that 162,000 individuals in the UK will be living with the condition. While existing drugs help to controlits symptoms, there are currently none available which slow or halt its progression.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - August 4, 2017 Category: Science Authors: Nicola Davis Tags: Medical research Parkinson's disease Diabetes Health Society Science Source Type: news

Diabetes drug could halt Parkinson's progression
Optimistic researchers say exenatide presents 'major new avenue for investigation' Related items fromOnMedica Many people ashamed to admit to Parkinson ’s disease Diabetes drug could protect against Parkinson ’s disease Hepatitis may increase risk of Parkinson's disease (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 4, 2017 Category: UK Health Source Type: news

Type 2 diabetes drug could combat Parkinson's
People with Parkinson ’s who took Exenatide – an existing diabetes medication - for around a year had better motor skills than those who took a placebo. (Source: the Mail online | Health)
Source: the Mail online | Health - August 3, 2017 Category: Consumer Health News Source Type: news

Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study suggests, paving the way for further research to define its efficacy and safety. The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF), found that people with Parkinson's who injected themselves each week with exenatide for one year performed better in movement (motor) tests than those who injected a placebo. (Source: World Pharma News)
Source: World Pharma News - August 3, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Bydureon (Exenatide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 20, 2017 Category: Drugs & Pharmacology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 14, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. BioStable Science & Engineering begins limited release of Haart 300 annuloplasty device Cardiovascular device developer BioStable Science & Engineering said today it began a limited launch ofits HAART 300 aortic annulop...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Delpor wins $1.5m NIH grant for diabetes drug implant
Delpor Inc. said today that it won a $1.5 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to support the development of its exenatide implant. The implant was designed for patients with Type II diabetes and features Delpor’s Nanopor technology, which uses passive diffusion to deliver therapeutic levels of exenatide for at least 3 months. Get the full story at our sister site, Drug Delivery Business News. The post Delpor wins $1.5m NIH grant for diabetes drug implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup Implants Pharmaceuticals delpor National Institutes of Health (NIH) Source Type: news

Delpor Awarded $1.5 million NIH Grant for Exenatide Implant for the...
The NIDDK continues to fund Delpor’s efforts to utilize its NANOPOR™ technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through...(PRWeb June 14, 2017)Read the full story at http://www.prweb.com/releases/2017/06/prweb14423867.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 14, 2017 Category: Pharmaceuticals Source Type: news

Fewer T2D Patients Advanced Therapy With GLP-1 Pump
(MedPage Today) -- Less need for additional drugs with implantable exenatide versus sitagliptin, placebo (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 12, 2017 Category: Primary Care Source Type: news

EXSCEL: No CV Benefit, but No Harm With Bydureon in Diabetes EXSCEL: No CV Benefit, but No Harm With Bydureon in Diabetes
Top-line results from the CV outcomes trial of once-weekly GLP-1 agonist, exenatide for diabetes show there's no indication of any CV harm, but there's also no benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

FDA accepts Intarcia ’ s NDA for diabetes drug-device combo
Intarcia Therapeutics said today that the FDA accepted its New Drug Application for the 1st drug to use Intarcia’s Medici drug delivery system to treat Type II diabetes. The Medici drug-device combo delivers exenatide subcutaneously using a match-sized osmotic pump placed under the skin in an in-office procedure. The subcutaneous delivery system uses technology to stabilize proteins, peptides, antibody fragments and other small molecules at or above human body temperatures for up to 3 years. Once the mini-pump is placed under the skin, water from extracellular fluid enters the device at ...
Source: Mass Device - February 6, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Wall Street Beat Intarcia Therapeutics Source Type: news

Byetta (Exenatide Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

Exenatide-Pioglitazone Combo Tops Insulin in Type 2 Diabetes Exenatide-Pioglitazone Combo Tops Insulin in Type 2 Diabetes
The combination lowers HbA1c more effectively with less weight gain and hypoglycemia in type 2 diabetes patients poorly controlled on metformin plus a sulfonylurea in the Qatar study.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 17, 2017 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Oramed touts phase Ib data for type 2 diabetes capsule
Oramed Pharmaceuticals (NSDQ:ORMP) said today that it finished a phase Ib study of its oral GLP-1 analog capsule for type 2 diabetes. Glucagon-like peptide-1 (GLP-1) is a hormone that stimulates the pancreas to secrete insulin. Exenatide, a GLP-1 analog, is available on the market as an injection for patients with type 2 diabetes. The analog stimulates insulin release at increased glucose levels and can result in reduced food intake, along with weight loss. Get the full story at our sister site, Drug Delivery Business News. The post Oramed touts phase Ib data for type 2 diabetes capsule appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 29, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Oramed Therapeutics Source Type: news

MassDevice.com +5 | The top 5 medtech stories for November 21, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Zimmer Biomet readies $1B tenders for senior debt Zimmer Biomet said today that it plans to float tender offers for some $1.1 billion worth of senior notes. The tenders are aimed at lowering the debt load it took on when Zimmer...
Source: Mass Device - November 21, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Intarcia seeks FDA nod for Medici drug delivery system
Intarcia Therapeutics said today that it submitted a New Drug Application to the FDA for its injection-free ITCA 650 candidate, the 1st drug to use Intarcia’s Medici drug delivery system to treat Type II diabetes. The ITCA 650 enables subcutaneous delivery of exenatide using a match-sized osmotic pump placed under the skin in an in-office procedure. With the NDA submission, the Boston-based company triggered a 3rd, $100 million milestone payment from the $300 million royalty financing put in place in the 2nd quarter of 2015. The milestone payment adds to the $215 million Intarcia raised in Se...
Source: Mass Device - November 21, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Implants Pharmaceuticals Regulatory/Clearance Intarcia Therapeutics Source Type: news